Companies › Zydus Lifesciences
1 active drug program in 1 registered trial: 1 Phase 4; Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Desidustat PHD inhibitor | EGLN1, EGLN2, EGLN3 | Phase 4 | Chronic Kidney Diseases | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05515367 | Desidustat | Phase 4 | Chronic Kidney Diseases | Genitourinary | Jun 2025 |
Fertility Center of Las Vegas Granata Bio Dimerix Bioscience Chengdu Qingshan Likang Pharmaceutical Hope Medicine (Nanjing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.